Seeking Alpha

Cytokinetics' (CYTK) shares plunge 11.9% after the company reported that an error in the Phase...

Cytokinetics' (CYTK) shares plunge 11.9% after the company reported that an error in the Phase II trial of its Tirasemtiv treatment for Lou Gehrig's disease caused 58 subjects to incorrectly receive a placebo rather than the drug.
Comments (1)
  • joe kelly
    , contributor
    Comments (1726) | Send Message
     
    Unhappy about this event as a holder of CYTK. On the other hand I'd just as soon lose the money invested and see this disease cured.

     

    There is no honor in biotech investing. NO matter what we tell ourselves.
    8 Jul 2013, 09:29 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|